Atanasio Pandiella

Atanasio Pandiella's AcademicInfluence.com Rankings

Atanasio Pandiella

Philosophy

#9674

World Rank

#13266

Historical Rank

Logic

#6643

World Rank

#8177

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Atanasio Pandiella's Degrees

PhD Biotechnology Complutense University of Madrid
Masters Biochemistry University of Barcelona
Bachelors Biology University of Valencia

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Atanasio Pandiella Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Atanasio Pandiella's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Membrane-anchored growth factors. (1993) (703)
Sox2 expression in breast tumours and activation in breast cancer stem cells (2012) (468)
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. (2002) (324)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors (2011) (256)
Neutrophils in cancer: prognostic role and therapeutic strategies (2017) (241)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. (2006) (240)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. (2006) (197)
Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process. (1991) (191)
Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2 (2002) (187)
Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (2008) (176)
HER3 overexpression and survival in solid tumors: a meta-analysis. (2013) (170)
Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-α-Converting Enzyme (2000) (166)
Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis (2014) (147)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma (2010) (144)
Preclinical development of molecular-targeted agents for cancer (2011) (137)
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors (2009) (133)
Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin. (1988) (131)
Medicinal Plants as Sources of Active Molecules Against COVID-19 (2020) (121)
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. (2008) (120)
Multiple signals activate cleavage of the membrane transforming growth factor-alpha precursor. (1991) (118)
Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. (1992) (116)
The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFα into soluble growth factor (1992) (115)
Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target (2009) (113)
Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma (2005) (113)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects (2013) (109)
TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment (1996) (107)
Neuregulins and Cancer (2008) (107)
Resistance to Antibody-Drug Conjugates. (2018) (106)
P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer (2011) (96)
Multifunctional role of Erk5 in multiple myeloma. (2005) (94)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma‐Initiating Cells that Infiltrate Peritumoral Tissue (2013) (88)
Ionic events induced by epidermal growth factor. Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell growth. (1991) (85)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. (2017) (84)
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer (2014) (84)
The effect of epidermal growth factor on membrane potential. Rapid hyperpolarization followed by persistent fluctuations. (1989) (82)
ω‐Conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines (1988) (82)
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. (2009) (81)
Autocrine Regulation of Membrane Transforming Growth Factor- Cleavage (*) (1996) (79)
TGF-β1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells (2006) (76)
ERK5 Activates NF-κB in Leukemic T Cells and Is Essential for Their Growth In Vivo1 (2006) (70)
Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. (2005) (69)
EGF raises cytosolic Ca2+ in A431 and Swiss 3T3 cells by a dual mechanism. Redistribution from intracellular stores and stimulated influx. (1987) (68)
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone (2014) (68)
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. (2008) (67)
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects (2012) (67)
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients (2012) (67)
Bortezomib is an efficient agent in plasma cell leukemias (2005) (66)
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents (2003) (65)
Personalized therapies in the cancer "omics" era (2010) (64)
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype (2008) (64)
Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. (2002) (63)
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair (2009) (60)
Endoglin Modulation of TGF-ß1-Induced Collagen Synthesis is Dependent on ERK1/2 MAPK Activation (2006) (60)
Activated release of membrane-anchored TGF-alpha in the absence of cytosol (1993) (59)
Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling‐competent truncated forms (1999) (58)
Role of metalloproteinases MMP‐9 and MT1‐MMP in CXCL12‐promoted myeloma cell invasion across basement membranes (2006) (58)
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. (2011) (58)
The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma (2014) (57)
Transforming growth factor‐β1 induces collagen synthesis and accumulation via p38 mitogen‐activated protein kinase (MAPK) pathway in cultured L6E9 myoblasts (2002) (57)
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling (2014) (55)
Stimulation of cleavage of membrane proteins by calmodulin inhibitors. (2000) (55)
Endoglin Expression Regulates Basal and TGF-β1-induced Extracellular Matrix Synthesis in Cultured L6E9 Myoblasts (2004) (55)
Voltage-operated calcium channels in small cell lung carcinoma cell lines: pharmacological, functional, and immunological properties. (1990) (54)
Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation (2010) (53)
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer (2017) (52)
Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers (2017) (52)
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. (2012) (51)
Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications (2012) (51)
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy (2009) (50)
Transmembrane signalling at epidermal growth factor receptors overexpressed in NIH 3T3 cells. Phosphoinositide hydrolysis, cytosolic Ca2+ increase and alkalinization correlate with epidermal-growth-factor-induced cell proliferation. (1988) (50)
Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. (2010) (49)
Impaired Trafficking and Activation of Tumor Necrosis Factor-α-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding* (2003) (48)
Multisite phosphorylation of Erk5 in mitosis (2010) (47)
Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor (2013) (47)
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. (2007) (47)
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer (2019) (46)
Targeting the EGF/HER Ligand-Receptor System in Cancer. (2016) (46)
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications (2012) (45)
Regulation of epidermal-growth-factor-receptor signal transduction by cis-unsaturated fatty acids. Evidence for a protein kinase C-independent mechanism. (1991) (45)
Transmembrane signalling at the epidermal growth factor receptor. (1989) (45)
Colorectal cancer and medicinal plants: Principle findings from recent studies. (2018) (45)
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. (2006) (45)
Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. (2007) (44)
Overexpression of HER2 signaling to WAVE2–Arp2/3 complex activates MMP-independent migration in breast cancer (2011) (44)
A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation (2004) (44)
Therapeutic potential of ERK5 targeting in triple negative breast cancer (2014) (44)
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. (2013) (43)
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options (2008) (43)
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease (2014) (43)
Erk5 is activated and acts as a survival factor in mitosis. (2007) (42)
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. (2014) (42)
TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. (2006) (41)
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies (2017) (41)
NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia (2014) (40)
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates (2020) (39)
Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. (2002) (38)
The insulin‐like growth factor‐I receptor inhibitor NVP‐AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells (2008) (36)
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity (2008) (36)
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy (2020) (36)
Deficient Spindle Assembly Checkpoint in Multiple Myeloma (2011) (36)
A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. (2002) (35)
Targeting HER receptors in cancer. (2012) (35)
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer (2017) (35)
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. (2020) (34)
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype (2012) (34)
ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA (2017) (33)
Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. (2014) (32)
Second-messenger generation in PC12 cells. Interactions between cyclic AMP and Ca2+ signals. (1988) (32)
β-Lapachone analogs with enhanced antiproliferative activity. (2012) (32)
Trastuzumab and Antiestrogen Therapy: Focus on Mechanisms of Action and Resistance (2006) (31)
Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis (2019) (31)
BET inhibitors as novel therapeutic agents in breast cancer (2017) (31)
Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis (2007) (30)
Breast Cancer Heterogeneity and Response to Novel Therapeutics (2020) (30)
Molecular Pathways: P-Rex in Cancer (2013) (30)
Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. (2007) (30)
Proteolysis targeting chimeras (PROTACs) in cancer therapy (2020) (30)
The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. (2006) (29)
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study (2019) (29)
Circulating DNA and Survival in Solid Tumors (2015) (29)
The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. (2008) (28)
Tumor-infiltrating lymphocytes in breast cancer: ready for prime time? (2015) (27)
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression (2016) (27)
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment (2020) (26)
Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. (2010) (26)
Intracellular Calcium Homeostasis in a Human Neuroblastoma Cell Line: Modulation by Depolarization, Cholinergic Receptors, and α‐Latrotoxin (1988) (26)
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses (2015) (26)
Plasma membrane hyperpolarization and [Ca2+]i increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: resemblance to early signals generated by platelet-derived growth factor. (1989) (25)
Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors (2017) (25)
The evolving landscape of protein kinases in breast cancer: clinical implications. (2013) (25)
Reinforcement of signal generation at B2 bradykinin receptors by insulin, epidermal growth factors, and other growth factors. (1989) (25)
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies (2020) (24)
Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer (2015) (24)
In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases (2016) (24)
Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors (2017) (22)
In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment (2016) (22)
Transforming growth factor-α (1991) (21)
Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. (1999) (21)
Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. (1993) (21)
Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free Ca2+ in rat somatotrophs. (1988) (20)
Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. (1989) (20)
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors (2019) (20)
Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. (2013) (20)
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1 (2020) (19)
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. (2017) (19)
N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. (2005) (19)
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome (2019) (19)
Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node (2016) (19)
Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. (2010) (19)
Erk 5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB 2 (2001) (19)
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies (2016) (19)
Antitumoral effect of Ocoxin on acute myeloid leukemia (2016) (18)
Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer (2015) (18)
Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine (2020) (18)
The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential (2014) (18)
Novel tyrosine kinase inhibitors in the treatment of cancer. (2009) (17)
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors (2020) (17)
Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2 (2015) (16)
Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling (2015) (16)
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor (2013) (16)
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response (2011) (15)
Refining Early Antitumoral Drug Development. (2018) (14)
Enhancement of antiproliferative activity by molecular simplification of catalpol. (2010) (14)
Do we have to change the way targeted drugs are developed? (2010) (14)
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs (2021) (14)
Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors (2017) (14)
Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer (2018) (13)
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2021) (13)
Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues. (1991) (13)
DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer (2016) (13)
Transcriptome evolution from breast epithelial cells to basal-like tumors (2017) (13)
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers (2013) (13)
Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester (2016) (12)
Protein kinase C-mediated feed back inhibition of the Ca2+ response at the EGF receptor. (1987) (12)
Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. (2019) (12)
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications (2013) (12)
Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results (2018) (12)
Functional transcriptomic annotation and protein–protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer (2018) (12)
Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors (2019) (11)
Antitumoral effect of Ocoxin in hepatocellular carcinoma (2017) (11)
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors (2019) (10)
Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy (2014) (10)
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. (2019) (10)
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer (2016) (9)
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. (2020) (9)
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer (2021) (9)
Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of Aristolochia longa L. (2017) (9)
CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2016) (9)
Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. (2019) (9)
Mapping Bromodomains in breast cancer and association with clinical outcome (2019) (9)
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer (2020) (8)
ERK 5 / BMK 1 Is a Novel Target of the Tumor Suppressor VHL : Implication in Clear Cell Renal Carcinoma (2013) (8)
Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. (2002) (8)
Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors (2015) (8)
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study (2017) (8)
Modulation of cereblon levels by anti-myeloma agents (2016) (8)
Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer (2018) (8)
Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer (2021) (8)
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21 (2021) (7)
MEK5 promotes lung adenocarcinoma (2018) (7)
A modular approach to trim cellular targets in anticancer drug discovery. (2011) (7)
Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin (2019) (6)
Therapeutic potential of ERK 5 targeting in triple negative breast cancer (2014) (6)
Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM (2011) (6)
Multisite phosphorylation of P-Rex1 by protein kinase C (2016) (6)
Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells. (2009) (5)
Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications (2017) (5)
Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene (2018) (5)
Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. (2005) (5)
Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis (2020) (5)
DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity (2008) (5)
Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer (2021) (5)
Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models (2019) (5)
Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model. (2007) (5)
PDCD4 limits prooncogenic neuregulin-ErbB signaling (2020) (5)
MZ1 co-operates with trastuzumab in HER2 positive breast cancer (2021) (4)
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. (2021) (4)
Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA‑MB 231 breast cancer cells. (2019) (4)
Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates (2022) (4)
The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity. (2007) (4)
The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation (2018) (4)
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors (2014) (4)
Antimyeloma Action of the Multikinase Inhibitor TG02 (2010) (4)
Generation of Antibody-Drug Conjugate Resistant Models (2021) (4)
Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer. (2017) (4)
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs (2017) (3)
Thyrotrophin‐Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin‐Releasing Hormone in Patients with Acromegaly or Cushing's Disease (1991) (3)
Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in cell cycle arrest (2007) (3)
Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors (1992) (3)
HER3 Overexpression and Survival in Solid Tumors (2012) (3)
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer (2020) (3)
Expression of the beta-isoforms of Na,K-ATPase in the renal cortex of rats. (1997) (3)
Growth Stimulation by Cell to Cell Contact and Growth Suppression: Two Aspects of the Biology of Transforming Growth Factors (1990) (3)
Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains* (2011) (3)
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer (2021) (3)
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer (2021) (3)
Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. (2016) (3)
CM 363 , a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2017) (2)
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer (2022) (2)
Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation (2021) (2)
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers (2022) (2)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
β-Lapachone Analogues with Enhanced Antiproliferative Activity. (2012) (2)
Voltage‐Operated Calcium‐Channel Subtypes in Human Neuroblastoma and Rat Pheochromocytoma Cells (1989) (2)
Genomic Correlates of DNA Damage in Breast Cancer Subtypes (2021) (2)
Targeting the mTOR pathway in ovarian cancer. (2010) (2)
Achilles' heel of triple negative cancer (2014) (2)
HER3 in cancer: from the bench to the bedside (2022) (2)
A Small Molecule Tubulin Depolymerizing Agent Identified by a Phenotypic Drug Discovery Approach (2018) (1)
Panobinostat (LBH589) a Promising New Partner for Combination with Doxorubicin in Acute Myeloid Leukemia. (2008) (1)
A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours (2019) (1)
Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients, (2011) (1)
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling (2014) (1)
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer (2021) (1)
Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects (2011) (1)
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis (2022) (1)
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma (2021) (1)
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma (2022) (1)
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. (2022) (1)
Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ) (2016) (1)
Abstract P3-14-11: Gene-expression analyses identify altered transcription factors and supports the antitumor activity of novel bromodomain inhibitors in triple negative breast cancer (2016) (1)
239PDA phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 (2017) (1)
Abstract P6-15-19: PI3K-MTOR Inhibitor BEZ235 Shows Antitumor Activity Against a Panel of Basal-Like Cells and Potentiates the Antitumor Activity of Taxanes and Vinorelbine (2010) (1)
An update into the pathophysiological role of HER2 in cancer: therapeutic implications (2007) (1)
Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage (2010) (1)
Alpha-1-Adrenergic Stimulation of Cytosolic Ca2+ Concentration and Growth Hormone (GH) in Rat Somatotrophs (1989) (1)
Antitumoral activity of EC70124, a novel multitarget kinase inhibitor, in triple-negative breast cancer. (2014) (1)
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer (2022) (1)
mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. (2022) (1)
Proteolysis targeting chimeras (PROTACs) in cancer therapy (2020) (0)
Neuregulin (NRG) expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (MBC). (2006) (0)
Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumours with favorable outcome (2019) (0)
Mitotic arrest induced by propargylic enol ethers derivatives (2010) (0)
Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04 (2016) (0)
Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells. (2006) (0)
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer (2022) (0)
Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer (2021) (0)
B195 DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity (2009) (0)
Abstract B39: Action of EC8042 in triple-negative breast cancer. (2011) (0)
Ocoxin oral solution demonstrates antiviral properties in cellular models (2021) (0)
Abstract 741: Targeting trastuzumab and T-DM-1 resistant breast cancer cells with EV20/MMAF, an antibody drug-conjugate against HER3 (2018) (0)
Ionic events induced by EGF: Intracellular Ca2+ release, Ca2+ influx and membrane hyperpolarization (1990) (0)
Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers (2017) (0)
What about incorporating selenium in the therapeutic regimen of SARS-CoV-2? (2020) (0)
Transforming Growth Factor (cid:2) Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (cid:1) † (2008) (0)
Preclinical Development Predominance of mTORC 1 over mTORC 2 in the Regulation of Proliferation of Ovarian Cancer Cells : Therapeutic Implications (2012) (0)
404 Multiple ErbBs Inhibition by Lapatinib Blocks Tumor Growth in Orthotopic Model of Human Testicular Germ Cell Tumour (2012) (0)
Abstract P4-06-17: Antitumor activity of the novel mithramycin analog EC8042 in triple negative breast cancer (2012) (0)
Role of c-Kit in Multiple Myeloma. (2006) (0)
Abstract P6-13-18: Triple-negative kinase profile guides in the selection of the multi-kinase inhibitor EC70124 as an active antitumor agent (2016) (0)
1600PPHOSPHO-KINASE EXPRESSION AND ANTI-TUMORAL ACTIVITY OF THE NOVEL MULTIKINASE INHIBITOR EC-70124 IN COLON CANCER. (2014) (0)
Lapatinib and Neratinib: Using combination drug therapy to advance the effect of the treatment of HER2 Positive Breast Cancer (2013) (0)
Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokine’s Production Pattern. (2005) (0)
[A new antigen for the complement fixation reaction in the diagnosis of toxoplasmosis]. (1968) (0)
Epigenetic mutational landscape in breast cancer: role of the histone methyltransferase gene KMT2D in triple negative tumors (2018) (0)
Cancer Therapy : Preclinical NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia (2014) (0)
Abstract A153: Effect of the multikinase inhibitor TG02 in HER2-positive breast cancer. (2011) (0)
In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer (2019) (0)
Neutrophils in cancer: prognostic role and therapeutic strategies (2017) (0)
Anti-proliferative activity of bromodomain inhibitors JQ1 and OTX015 in triple negative breast cancer. (2015) (0)
676 HER3 Expression in Human Breast Carcinomas is Associated With Tumor Size and Estrogen Receptor Status (2012) (0)
[Comparative study of trypanolysis and complement fixation reaction in guinea pigs infected with "Trypanosoma crusi"]. (1967) (0)
ction of B-Chronic Lymphocytic Leukemia Cell ptosis by Arsenic Trioxide Involves Suppression of the sphoinositide 3-Kinase/Akt Survival Pathway via (2010) (0)
Transforming growth factor-alpha. (1991) (0)
Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease. (2009) (0)
Ionic signals generated by growth factors: Modulation by protein kinase C (1988) (0)
Mechanisms of Action of Growth Factors (1989) (0)
B331 Tyrosine Kinase Inhibition in MM? Efficacy of the Combination of Dasatinib/Bortezomib/Dexamethasone (2009) (0)
Development of 99mTcHYNIC-Tocilizumab as Imaging Agent In Multiple Myeloma (2010) (0)
PDCD4 limits prooncogenic neuregulin-ErbB signaling (2020) (0)
83 Effect of TG02, a kinase inhibitor targeting Erk5, on triple negative breast cancer cells (2010) (0)
1204 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs (2015) (0)
Mapping Bromodomains in breast cancer and association with clinical outcome (2019) (0)
Achilles' heel of triple negative cancer (2014) (0)
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer (2019) (0)
Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease (2012) (0)
Cancer Biology and Signal Transduction Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC 1 Inhibition as an Antimyeloma Strategy (2014) (0)
Zalypsis Possess Potent Antileukemic Effect through the Induction of a DNA Damage Response, Independently of the p53 Status. (2009) (0)
ω-Conotoxin binding and function in human neuroblastoma and rat pheochromo- cytoma cell lines (1988) (0)
Abstract P4-10-11: PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials (2020) (0)
Genomic mapping to identify mutations in RYR2 and AHNAK in basal-like breast tumors expressing PD-L1. (2020) (0)
Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer (2012) (0)
Acadesine Inhibits Proliferation and Induces Apoptosis In Multiple Myeloma Cells, and Synergizes with Standard of Care Antimyeloma Agents (2010) (0)
91P Transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2020) (0)
Abstract C66: Role of mTORC1 and mTORC2 in multiple myeloma and their targeting with CC214. (2011) (0)
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer (2021) (0)
Pharmacological screening with Chk1 inhibitors identifies synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer (2019) (0)
Abstract B268: Tyrosine kinase profiling in head and neck cancer tumors in combination with clinical prognosis factors guides therapeutic combination strategies (2009) (0)
A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs (2010) (0)
337 Differential action of ErbB kinase inhibitors on receptor oligomerization (2010) (0)
Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors (2012) (0)
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors (2013) (0)
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma (2021) (0)
MEMBRANE-ANCHORE D GROWTH FACTORS (1993) (0)
A new antigen for the complement-fixation test for the diagnosis of toxoplasmosis. (1968) (0)
Tyrosine kinase profiling guides combined therapeutic strategies in head and neck cancer. (2009) (0)
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer (2022) (0)
and decreases the production of Th1 cytokines Bortezomib induces selective depletion of alloreactive T lymphocytes (2012) (0)
Abstract 1608: Pharmacologic screening identifies synthetic lethality interactions with Chk1 inhibitors in basal-like breast and ovarian cancer (2018) (0)
Abstract P6-05-04: Expression of the Androgen Receptor in triple negative tumors and its modulation by receptor tyrosine kinases and downstream pathways (2012) (0)
P3-16-14: Effect of TG02, a Multikinase Inhibitor, on Triple Negative Breast Cancer Cells. (2011) (0)
Erratum: Achilles' heel of triple negative cancer (2014) (0)
Comparisson of Molecular Mechanisms Altered by Treatment with Different Drugs ( Doxorubicin, Melphalan, Bortezomib, Aplidin and Arsenic Trioxide ) in Multiple Myeloma Patients Using Oligonucleotide Microarrays. (2004) (0)
Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia (2018) (0)
10P Genomic profiles of CD47 in breast tumours predict outcome and are associated with immune activation and enrichment of pro-tumoral macrophage markers (2020) (0)
Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer (2017) (0)
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology (2022) (0)
Cancer Therapy : Preclinical Potent Antimyeloma Activity of a Novel ERK 5 / CDK Inhibitor (2013) (0)
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs (2017) (0)
Traitements du myélome multiple (2009) (0)
Genomic mapping of copy number variations influencing immune response in breast cancer (2022) (0)
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates (2020) (0)
Molecular Pathways Molecular Pathways : P-Rex in Cancer (2013) (0)
MZ1 co-operates with trastuzumab in HER2 positive breast cancer (2021) (0)
ODZ1 supports glioblastoma progression by enhancing proliferation and migration of cancer stem-like cells (2019) (0)
Intracellular Ca2+ homeostasis: Cell biology and activation of rapidly exchanging Ca2+ stores (1989) (0)
What about incorporating vitamins D and C supplementation in the prevention and treatment of COVID-19? The immune response pathway (2020) (0)
Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer (2023) (0)
The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib (2023) (0)
Studies on Voltage-Gated Calcium Channels by Means of Fluorescent [Ca2+]i Indicators (1988) (0)
The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Atanasio Pandiella?

Atanasio Pandiella is affiliated with the following schools:

University of Milan
Complutense University of Madrid
University of Valencia
University of Salamanca
University of Barcelona

Atanasio Pandiella's Academic­Influence.com Rankings